The use of viral vectors for gene delivery to motor neurons in vivo has been hampered by the need to perform invasive surgery to inject directly the vector into the anterior horn of the spinal cord. Here, we have characterized the features of herpes simplex virus-1 (HSV)-derived vectors, in terms of gene mutations and promoter constructs, that are required to allow efficient transduction of motor neurons following a relatively noninvasive peripheral administration via sciatic nerve or footpad injection. Owing to the wide variety of animal models used to study neurodegenerative diseases of motor neurons, we analysed the effectiveness of these vectors in adult mice and adult and neonatal rats. We tested viruses with differing degrees of disablement based on the 1764 backbone (deleted for ICP34.5 and an insertional inactivation in VP16) rendered completely replication incompetent by the deletion of the essential immediate-early genes ICP27 and/or ICP4. In the adult mouse, prolonged gene expression in motor neurons was obtained after sciatic nerve inoculation with a vector defective in ICP4 and ICP27. In the adult rat, both the vector defective in ICP4 and the vector defective in ICP4 and ICP27 were capable of transducing motor neurons for extended periods of time during viral latency. This study demonstrates the feasibility of using HSV vectors for persistent transgene expression in motor neurons in a safe and nontoxic manner following peripheral administration. These vectors are potentially useful tools to investigate the functions of genes involved in motor neuronal survival and regeneration in models of motor neuron diseases in vivo.
Introduction
Motor neuron diseases, such as amyotrophic lateral sclerosis (ALS), are adult onset neurodegenerative disorders that are characterized by motor neuron degeneration and loss, resulting in paralysis and ultimately death. 1 At present there is no effective treatment. However, many neurotrophic factors have been suggested to be of therapeutic use for the treatment of motor neuron disease both by increasing motor neuron survival, thus halting disease progression, and by reversing the neuronal degeneration that has already taken place by promoting axonal regeneration. [2] [3] [4] [5] [6] [7] [8] Despite this potential, administration of these substances has been of limited success either due to poor tissue penetration and bioavailability 9 or due to serious side effects when doses sufficient to be efficacious were administered systemically. 10 Gene therapy using viral vectors to deliver neurotrophic factors directly and specifically to the affected motor neurons is an attractive approach to overcome these problems.
Although several studies have shown gene delivery to cultured motor neurons in vitro, 11, 12 a much smaller number of studies have shown efficient gene delivery in vivo. Most in vivo gene delivery to motor neurons has involved direct stereotaxic injections of the vector to the cell bodies of motor neurons in the ventral spinal cord. A number of laboratories (including our own) have used this approach with different viral vectors, including adenovirus, 13 adeno-associated virus, [14] [15] [16] lentivirus, 17 polio virus 18 and herpes simplex virus (HSV), [19] [20] [21] with differing degrees of success. Although this approach does indeed result in the transduction of motor neurons, there is inevitably some trauma associated with the direct injection. In addition, there is a lack of cell type specificity due to the transduction of other cell types in the spinal cord around the site of injection.
Motor neurons have a large soma located in the ventral horn of the spinal cord in the central nervous system and they project a long axon into the periphery to innervate skeletal muscles.
This ideally allows for a vector to be delivered to the motor neuron via a peripheral inoculation. Adenoassociated viruses have been shown to undergo motor neuron retrograde transport, [22] [23] [24] and this property was successfully harnessed to deliver insulin growth factor 1 to mice overexpressing mutant superoxide dismutase-1 following intramuscular injection. 25 Other gene therapy studies on mouse models of ALS used adenovirus vectors [26] [27] [28] delivered intramuscularly. The results obtained, however, relied on the ability of the gene product, and not the vector itself, to be retrogradely transported to the motor neurons from the muscle fibres.
Here, we have characterized the use of disabled genomic HSV vectors that, following peripheral administration, undergo retrograde axonal transport to the cell body in the spinal cord where they can allow the expression of potentially therapeutic genes. The use of these vectors will allow the therapeutic value of gene products to be evaluated without excessive trauma or invasive surgery, potential side effects due to high systemic levels of vector, the delivery of gene products to irrelevant cells or the high financial cost associated with repeated systemic neurotrophic factor delivery.
Genomic HSV vectors have many properties that make them highly attractive for the purpose of gene delivery to motor neurons in vivo following peripheral inoculation. HSV naturally infects postmitotic cells including neurons. It is a large virus with a genome of 152 kb and much of the genetic material in this genome can be replaced by transgenes without significantly altering the properties of the virus, thus allowing up to 30 kb of exogenous genetic material to be inserted. This means that large or multiple transgenes can be expressed from the one viral construct. 29 After infection, HSV is retrogradely transported to the cell body where it naturally enters a latent state where the genome is maintained for the lifetime of the infected cell. The vector does not integrate into the host cell genome, therefore avoiding the possibility of insertional activation or inactivation of host cell genes. The lifetime presence of the HSV genome within the host cell as a nuclear extrachromosomal entity allows the possibility of longterm transgene expression.
During HSV-1 latency, the activity of both endogenous and exogenous promoters are suppressed except for a unique region of the HSV-1 genome that remains transcriptionally active. This region, called the latencyassociated transcript (LAT), produces a messenger RNA species during latency utilizing two promoter regions (LAT P1 and LAT P2). 30 Previously, we have shown that these promoter regions can confer long-term activity onto neighbouring exogenous promoters allowing the expression of genes in neurons for extended periods of time overcoming the suppression normally associated with the onset of viral latency. 21, 29 Previous studies have used herpes viral vectors (either amplicons, disabled genomic vectors or attenuated mutants) for gene delivery to motor neurons following peripheral inoculation. [31] [32] [33] [34] In the studies using disabled genomic vectors, 33, 34 it was shown that HSV vectors are indeed capable of undergoing retrograde transport in motor neurons and are also capable of mediating transgene delivery. However, these disabled vectors were associated with a certain degree of cytotoxicity 33 and were not capable of driving long-term transgene expression. 33, 34 In this study, we have investigated a series of disabled HSV-1-based genomic vectors with different degrees of disablement and different promoter constructs in order to elucidate the best combination for efficient nontoxic long-term gene delivery to motor neurons in vivo following peripheral administration. Secondly, due to the variety of animal models associated with the study of motor neuron diseases (transgenic mice and neonatal axotomy and ventral root avulsion in rats), we have assessed the use of these vectors in adult mice and adult and neonatal rats. Thirdly, we have also investigated the effects of the immune system on gene delivery by comparing the levels of gene expression in wild-type and severe combined immunodeficient (SCID) mice.
The results obtained here demonstrate the utility of disabled HSV-1 vectors containing the appropriate promoter constructs as tools to elucidate the possible physiological function of neurotrophic factors and other proteins on motor neuron survival and regeneration in vivo following peripheral administration.
Results
The various viral backbones and promoter constructs used in this study are shown diagrammatically in Figure 1 .
Use of various disabled HSV vectors for gene delivery to adult mouse motor neurons and dorsal root ganglion (DRG) neurons in vivo
The ability of the vectors 1764pR20.5, 1764pR20.9, 1764 4-pR19LacZ and 1764 27-4-pR19LacZ to mediate gene delivery to motor neurons and DRG neurons in vivo following peripheral inoculation was tested. Footpad inoculation of 1764pR20.9 and sciatic nerve inoculation of 1764pR20.5 resulted in high levels of gene delivery to motor neurons and DRG neurons 2 days following inoculation (Table 1 and Figures 2 and 3 ). Positive motor neurons were observed in the lumbar region of the spinal cord ipsilateral to the injection site. This is in accordance with the location of motor neurons that project into the sciatic nerve. No gene expression was observed in motor neurons or DRG neurons contralateral to the injection Figure 1 Schematic diagram of the viruses (a) and promoter constructs (b) used in this study. The arrows in (a) indicate the site of insertion in the HSV genome of the promoter constructs. The pR20.5 and pR20.9 cassettes were inserted into the UL43 gene of vectors deficient for ICP34.5 and VP16. The pR19LacZ cassette was inserted into the LAT region of replication-incompetent vectors deficient for ICP34.5, VP16, ICP4 and/or ICP27.
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MCP Perez et al site or in any postsynaptic neurons or in any other region of the spinal cord or nervous system, indicating the lack of transynaptic spread with these attenuated vectors. High levels of gene expression were seen with both axonal processes and cell soma showing robust staining for LacZ. GFP was also detected in the same neurons (data not shown), as for our previous work in which these promoter constructs have been used. 21, 29 Although inoculation with 1764pR20.5 and 1764pR20.9 resulted in high levels of gene expression 2 days after inoculation, extensive mononuclear cell infiltration can be seen (Figures 2b, c and 3b, c) . Gene expression can be observed in DRG neurons at later time points (Figures 2d and 3d ), but the number of expressing motor neurons is greatly reduced (Table 1 and Figures 2e, f and 3e, f). In the lumbar region of the spinal cord ipsilateral to the injection site nuclear debris and extensive mononuclear infiltrates can be seen, indicative of an inflammatory response. Similar infiltrates and necrotic neurons have previously been seen as early as 3 days following intramuscular injection of wild-type HSV and HSV-based vectors. 33, 35 Following sciatic inoculation of vector 1764 4-pR19LacZ robust X-gal staining was seen in DRG and motor neurons at 2 days and 2 weeks (Table 1 and Figure  4a -f). However, at longer time points (1 month) transgene expression was undetectable (Figure 4g-i) .
Sciatic nerve injection of 1764 27-4-pR19LacZ gave long-term gene expression in the lumbar motor neuron and DRG neurons (Table 1 and Figure 5 ). Gene expression with this highly disabled replication-incompetent vectors was seen to be stable with similar levels of gene expression seen 2 days, 2 weeks and 1 month following inoculation ( Figure 5 ). Very little pathological changes were observed in the spinal cord following administration of these vectors. Motor neurons ipsilateral to the injection site appeared healthy and indistinguishable from those on the contralateral side. Some positive motor neurons appeared to have a speckled pattern of staining as has previously been reported for both motor 34 and sensory neurons. 30 These results show that a replication-incompetent, highly disabled HSV vector in combination with a promoter construct incorporating the LAT P2 region of the herpes genome allows long-term gene expression to both motor neurons and DRG neurons during latency.
Effects of the immune system on gene delivery
Owing to the short-term nature of transgene expression following peripheral inoculation with vectors 1764pR20.5 and 1764pR20.9, the effects of the immune system were assessed by comparing gene expression in BALB/c and SCID mice. When transgene expression in DRG neurons of SCID mice was compared to BALB/c mice, an increase in the number of expressing neurons was seen ( Figure 6 ). This became apparent at 3 weeks (Figure 6c and h) and was pronounced at 2 months (Figure 6e and j). At 2 weeks following inoculation, the number of LacZ-expressing motor neurons in the spinal cord is also greater in SCID compared to BALB/c mice (Table 1 and Figure 7 ). There is also a dramatic reduction in the amount of mononuclear infiltration in SCID (Figure 7e and f) that is not observed in SCID mice (Figure 7k and l).
Gene delivery to the adult rat
Following peripheral inoculation of 1764pR20.5 and 1764pR20.9 into the footpad and sciatic nerve of adult rats, no gene delivery was seen in DRG or motor neurons at 2 days or 2 weeks (data not shown).
Injection of the replication-incompetent viruses 1764 4-pR19LacZ or 1764 27-4-pR19LacZ into the sciatic nerve of adult rats resulted in b-galactosidase expression in sensory neurons in the DRG and motor neurons in the lumbar spinal cord ipsilateral to the injection site (Table 1 and Figure 8 ). The level of gene expression obtained with these viruses was maintained for at least 1 month for 1764 4-pR19LacZ and 2 weeks for 1764 27-4-pR19LacZ. Although longer time points were not tested with these viruses, it might be expected that expression would be maintained as this was seen following direct injection into the spinal cord. 21 Following the inoculation of replication-incompetent vectors, very little cell debris and cell infiltration was observed in the spinal cord indicative of the low immunogenicity of these vectors.
Gene delivery to the neonatal rat
Unlike the situation in the adult rat, injection of 1764 pR20.9 into the footpad of neonatal rats resulted in high levels of transgene expression in sensory neurons in the DRG ipsilateral to the site of inoculation (Figure 9a) . A dramatic reduction in the number of transgene-expres- 
HSV-1 vectors for gene delivery to motor neurons
MCP Perez et al sing neurons was seen at 2 weeks, which might be indicative of a maturing immune system. The efficiency of motor neuron transduction following footpad inoculation in neonatal rats was very low with expression only observed at 2 days postinoculation (Table 1 and Figure  9b ). In contrast to the situation described above, direct inoculation of vector 1764 pR20.5 into the sciatic nerve of neonatal rats resulted in highly efficient gene delivery to motor neurons (Table 1 and Figure 9d) . However, the level of expression in DRG neurons was low (Figure 9c ) and gene expression in both motor neurons and DRG neurons had decreased dramatically by 1 week postinoculation (Figure 9e and f) . In addition, unlike the 
HSV-
-pR19LacZ, extensive motor neuron loss was seen in the spinal cord and this was accompanied by cell debris. However, in line with the immaturity of the immune system in neonatal animals, very little evidence of infiltrating cells or of an active immune response was observed. Neonatal motor neurons are, however, exquisitely sensitive to mechanical injury, 36 and the reduction in gene expression seen may be due to the cytotoxicity of the 1764 viruses.
Injection of the vector 1764 27-4-pR19LacZ into the sciatic nerve of neonatal rats resulted in gene expression in both sensory neurons in the DRG and motor neurons in the spinal cord 2 days after gene delivery (see Table 1 ). However, unlike the stable gene expression observed with this vector in the adult rat and mouse, the number of LacZ-expressing motor neurons decreased significantly 1 week following inoculation. No immune response was observed and there appeared to be no loss of motor neurons with this vector (unlike the 1764 vectors), although due to the low transduction efficiency in this situation the loss of motor neurons may be difficult to detect.
Owing to the sensitivity to mechanical damage of neonatal motor neurons, an injection of phosphatebuffered saline was made into the sciatic nerve of neonatal rats. At 1 week following this injection, no cell death could be seen (data not shown). This indicated that Figure 7 Comparative in vivo gene delivery to motor neurons of BALB/c (a-f) and SCID (g-l) mice after intraplantar inoculation of 1764 pR20.9. Spinal cords were removed, sectioned and stained for LacZ activity 2 days, 2 weeks and 2 months postinoculation. (b, d, h and j) Are enlargements of the boxed regions in (a, c, g and i), respectively. Cell infiltrates (arrows) can be seen in both BALB/c mice (at 2 days and 2 weeks) and SCID mice (only at 2 days). By 2 months, extensive motor neuron loss (boxed region in f) is seen in BALB/c mice but not SCID mice ipsilateral to the injection site (compare f to l). In SCID mice 2 months after inoculation, the contralateral (k) and ipsilateral (l) sides of the spinal cord are indistinguishable from each other. In vivo gene delivery to the DRG (a) and motor neurons (b) of the neonatal Lewis rat following intraplantar inoculation with the vector 1764 pR20.9. DRG and spinal cords were stained for LacZ 2 days postinoculation. In vivo gene delivery to the DRG (c and e) and motor neurons (d and f) of neonatal rats following sciatic nerve inoculation of the vector 1764 pR20.5. DRG and spinal cords were removed 2 days and 2 weeks following inoculation. Motor neuron loss can be seen at 1 week ipsilateral to the injection site (area in the box in f).
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Discussion
Although the use of HSV vectors to deliver genes to DRG via a peripheral route has been previously demonstrated, the properties required of an HSV vector to allow efficient gene delivery to motor neurons via a peripheral route has not been as extensively studied. Most vectors that allow efficient delivery to motor neurons require either direct injection, 19, 20 are uncharacterised mutants, 32 or retain some pathogenicity when used in vivo. 33 In this study, we have assessed the properties of HSV vectors, in terms of gene mutations and promoter constructs, that allow the vector to retain the ability to efficiently mediate nontoxic gene delivery to sensory neurons of the DRG of the peripheral nervous system and motor neurons of the central nervous system following peripheral administration. Owing to the numerous different models used to study motor neuron survival and regeneration, we have tested gene delivery in adult mice (transgenic animals), adult rats (ventral root avulsion) and neonatal rats (axotomy to study motor neuron survival). In this study, we have tested viruses with three different levels of disablement, namely, 1764, 1764 4-and 1764 27-4-. These are based on the 1764 backbone that has a deletion in ICP34.5 and an insertional inactivation in VP16, thus dramatically reducing the pathogenicity of the vector, but not completely preventing viral replication. Replication-incompetent vectors with further disablements in the essential immediate-early genes ICP4 and ICP27 that are absolutely required for viral replication were also tested. Particularly relevant for transgene expression is the LATP2 region, which we have previously identified as a region of DNA that can confer latent gene expression properties onto heterologous promoters or LAP1 even when these promoter cassettes are inserted into nonLAT sites in the viral genome. 29 Different promoter constructs that include regions of the latency-associated promoters that have previously been shown to be essential for longterm gene expression during viral latency were also tested. 21, 29 In the adult mouse, replication-competent vectors were capable of high levels of transgene expression in motor neurons after either footpad or sciatic nerve inoculation, although these vectors are incapable of driving long-term expression in this context. The promoter constructs used in these vectors allows for the expression of two transgenes, and we found that levels of GFP were similar to the levels observed for LacZ. Indeed, both 1764 pR20.9 and 1764 pR20.5 have previously been shown to allow gene expression of both GFP and LacZ in mouse DRG. 29 In addition, the pR20.5 cassette has also been shown to drive both GFP and LacZ in organotypic hippocampal slice cultures. 21 Sciatic nerve inoculation of 1764 4-pR19LacZ resulted in robust staining in motor neurons and DRG at short time points, but this expression was not maintained at 1 month. This vector appears to be more efficient for transgene delivery than the 1764-based vectors, but may have sufficient viral gene expression to be toxic at long time points. In contrast to the situations described above, sciatic nerve inoculation of the replication-incompetent vector 1764 27-4-pR19LacZ in adult mice resulted in long-term gene expression (in both DRG and motor neurons) that was stable for at least a month. The use of replicationincompetent HSV vectors for long-term gene delivery to adult mouse DRG has also been shown by others, 37 using a virus with a temperature-sensitive mutation in ICP4, an inactivating mutation in VP16 and a partial deletion of ICP0. The replication-incompetent vector we used is nontoxic, which expresses very little viral gene products 21 and contains a promoter construct that has the strong CMV promoter downstream of the LAT P2 region. This vector has previously been shown to allow gene expression during latency. 21 Long-term transgene expression has already been reported in motor neurons after intramuscular injection of an HSV virus, but the vector used was an attenuated replicating mutant strain selected from an HSV-1 library. 32 Previous studies that have shown gene delivery to motor neurons following distal inoculation of disabled HSV vectors have resulted in transient short-term gene expression. 33, 34 Although other studies have shown gene expression in motor neurons with HSV disabled vectors, these have required direct injection into the spinal cord using invasive and complicated surgery. [19] [20] [21] To our knowledge, the present study is the first to demonstrate the use of a replicationincompetent HSV vector for long-term gene delivery to motor neurons following peripheral inoculation by a relatively noninvasive procedure.
We observed that the extent and time course of gene expression in sensory neurons and motor neurons was different. This is unsurprising when the different environments of these neuronal populations are considered; sensory neurons are components of the peripheral nervous system, whereas motor neurons are found in the spinal cord of the central nervous system. Furthermore, HSV-1 naturally infects and establishes latency in DRG neurons. It is known that intramuscular injection of wildtype HSV-1 results in limited productive viral infection and good cell survival in the DRG, whereas extensive necrosis and viral spread was seen in the region of the motor neurons in the anterior spinal cord. 35 Differences in transcription factors could also be responsible for the ability of the vector to establish latency in one particular cell type. 38 Studies using an HSV-1-derived vector containing the LAP1-MMLV-LTR LacZ construct in the gC locus have also reported differences in the efficiency of gene delivery where, following intramuscular inoculation, long-term transgene expression was seen in the DRG 39 but not in motor neurons. 33 The inability to obtain long-term gene delivery with the replication-competent vectors used here is at least partially due to an adaptive immune response. The cell infiltrates and debris seen in the spinal cord around motor neurons were very similar to those seen by others following intramuscular delivery of replication-incompetent viruses. 33, 35 The influence of the host's adaptive immune response on the efficiency of gene delivery by replication-competent vectors is also supported by the reduction in mononuclear cell infiltration and inflammation seen in SCID compared to BALB/c mice. Of particular interest here is a previous study that examined the immune response in the brain following direct injection of an HSV-1 vector deleted for both copies of
40 At 3 days postinoculation, a nonspecific immune response was seen with the accumulation of macrophages around the injection site. By 1 week this infiltration was extensive and was more specific with the inclusion of T cells. Our results support this observation where, at early time points in both BALB/c and SCID mice, macrophages were present (as SCID mice still have a nonadaptive immune response), but at later time points considerably less cell infiltration was seen in SCID mice. At the later time points these infiltrates consist mainly of T cells and T-cell-activated macrophages (which are not present in SCID mice), and as a consequence there is no amplification of the immune response in the SCID animals compared to BALB/c mice. The results obtained with SCID mice also support our previous study where we showed that following peripheral inoculation of 1764pR20.9, the number of cells in the DRG-expressing LacZ protein was similar to the number of cells that expressed LAT mRNA, suggesting that the promoter was not being repressed in this situation but that virus was being cleared. 29 Rats were seen to be much less susceptible to HSV-1 infection than BALB/c mice. This has been seen previously and was attributed to a difference in the host nonadaptive immune system. 41 Transduction of motor neurons in the adult rat using disabled HSV vectors has only been reported following direct spinal cord injection. [19] [20] [21] These reports used replication-incompetent vectors: the 1764 27-4-pR19LacZ vector 21 and a vector defective for ICP4, ICP22 and ICP27 with an insertion in the TK locus. 19, 20 Indeed, in our present study the efficiency of transduction was greater with replicationincompetent vectors than replication-competent vectors. Interestingly, other studies on HSV-mediated gene delivery to adult rat DRG following peripheral inoculation have used replication-incompetent vectors. 42, 43 A vector defective in ICP4, ICP27, ICP22 and ICP47 was used to deliver NT-3 and prevent the progression of neuropathy in an adult rat model, 43 and a vector deleted for ICP4 with a transgene expression cassette in the TK locus was used to modify pain-related behaviour in the adult rat. 42 The greater effectiveness of replicationincompetent vectors may be due to clearance of replication-competent virus by an immune reaction before efficient gene transfer can be detected. This clearance may even be occurring at the site of inoculation before the vector has reached the neuronal cell body. This theory is substantiated by our observation that gene delivery was more efficient in neonatal animals that have an immature immune system. Indeed, sciatic nerve inoculation of vector 1764 pR20.5 in the neonate rat gave the highest levels of gene expression in motor neurons that we saw in any situation. Interestingly, many of the studies using adenoviral vectors have used neonatal animals for this reason. [44] [45] [46] However, long-term gene expression in neonatal rats was problematic. Both sensory neurons and motor neurons are very sensitive to damage in the first few days of postnatal life. Replication-competent viruses may be too toxic for fragile, immature neurons, but the reduction in expression with replication-incompetent vector 1764 27-4-pR19LacZ in the neonatal rat is more difficult to explain. The inability to detect neuronal death in these animals does not necessarily signify that is it not occurring, as the clearance of the small number of neurons initially transduced would be difficult to detect. A PCR to detect viral genomes would demonstrate whether loss of expression was related to promoter shutdown or loss of vector genome but, nevertheless, it would not show the number of cells transduced. However, based on our previous studies, we would not expect replicationincompetent vectors to be cytotoxic as this is not the case in adult DRG neurons, spinal cord or brain. 21, 29 Excessive viral gene expression, particularly that associated with viral replication, will trigger an immune response that will clear the virus and infected neurons. The vector 1764 27-4-pR19LacZ has such low levels of HSV gene expression 21 that it may well escape immune clearance, but a concern was that it may be too disabled to allow efficient gene delivery via a peripheral route. However, in this situation it appears that the vector 1764 4-pR19LacZ is an ideal vector for this purpose. This vector is replication incompetent and, as such, has very limited viral gene expression, but is not sufficiently disabled to prevent efficient infectivity, transport and transduction of adult rat motor neurons. This vector gave high levels of LacZ expression in motor neurons for extended periods of time. It is curious that in the adult rat, both the vector deleted for ICP4 and the vector defective for ICP4 and ICP27 are capable of directing long-term gene expression following sciatic nerve inoculation, whereas in the adult mouse only the vector defective in ICP4 and ICP27 is capable of doing so. The reasons for this remain unclear, but it does seem that given that none of the vectors tested expressing ICP27 were capable of providing prolonged transgene expression in the adult mouse, the ICP27 gene product is more deleterious in this animal than it is in the adult rat.
Overall, this study has defined the parameters that enable disabled genomic HSV-1 vectors to mediate efficient long-term gene delivery to motor neurons following peripheral inoculation. We have shown that it is possible to achieve long-term stable gene expression in the adult mouse, which could be of use in transgenic animals in the study of the effects of particular molecules on motor neuron regeneration or survival when delivered to a defined motor pool in a relatively noninvasive way at a defined moment in time. We have also developed nonpathogenic safe vectors that are of potential use in neonatal axotomy models where motor neurons are lost shortly after injury. These vectors would aid the study of neurotrophic (and other) factors that are of potential therapeutic use in motor neuronal survival. The ability of these vectors to be administered peripherally is a significant advantage over direct inoculation into the spinal cord in that it is a relatively noninvasive and nontraumatic and, additionally, allows targeted gene delivery specifically to the neurons projecting to the site of injection.
Materials and methods

Vector construction
The generation of the disabled HSV vectors (1764 and 1764 27-4-) and the promoter constructs (pR20. 5, pR20.9 and pR19) have been described previously. 21, 29, 47 These vectors are based on wild-type HSV strain 17 þ . 48 A deletion in both copies of ICP34.5 49 and an inactivating mutation in VP16 is indicated by 1764; 50 1764 4-refers to a 1764 backbone with both copies of ICP4 deleted and 1764 HSV-1 vectors for gene delivery to motor neurons MCP Perez et al 27-4-refers to a 1764 backbone with both copies of ICP4 deleted and a further deletion in ICP27 21, 51 (see Figure 1 ). The bicistronic promoter constructs pR20.5 and pR20.9 were inserted into the UL43 gene of 1764 backbone at the unique NsiI site (nucleotide 94 911), and the resulting vectors were termed 1764pR20.5 and 1764pR20.9, respectively 29 (see Figure 1) . The pR19LacZ constructs were recombined into the endogenous LAT region of 1764 4-and 1764 27-4-viral backbone between the two BstXI sites (nucleotides 120 220 and 120 408), 21, 29 and the resulting vectors were termed 1764 4-pR19LacZ and 1764 27-4-pR19LacZ, respectively (see Figure 1) . Viral vectors were propagated by standard cell culture procedures on BHK cells or 27/12/M:4 cells (BHK cells that complement deletions in ICP4, ICP27 and vmw65) 51 in DMEM plus 10% fetal calf serum with 3 mM HMBA to complement for the mutation in VP16. Viral stocks were freeze-thawed and cell debris was removed by centrifugation at 3500 rpm for 45 min. The supernatant was further purified by filtration through 45 mm filters. The resulting filtrate was then concentrated by centrifugation at 12 000 rpm for 2 h and the viral pellet resuspended in a small volume of serum-free DMEM. Viral stocks were then stored in liquid nitrogen until use.
Animal procedures
BALB/c mice (3 weeks old), adult Lewis rats (220-250 g) and postnatal day 2 (P2) Lewis rat pups (Harlan, UK) were used in this study. All procedures involving animals followed the guidelines for the care and use of experimental animals of University College London and were performed in accordance with the UK Animals (Scientific Procedures) Act (1986).
All surgical procedures were performed under brief volatile anaesthesia (3% isofluothane in oxygen). For footpad inoculation, 25 ml of viral stocks of 1 Â 10 8 PFU/ ml was injected subcutaneously into the plantar surface on the left hindpaw. For sciatic nerve inoculation, the sciatic nerve was exposed at midthigh level by blunt dissection and 2-5 ml of 1 Â 10 8 PFU/ml of viral stock was injected via a pulled glass micropipette attached to a Hamilton microsyringe. At various time points postinoculation, animals (n ¼ 3 for each time point) were euthanized, under deep anaesthesia with sodium pentobarbitone, by transcardial perfusion with ice-cold 4% paraformaldehyde (PFA). The lumbar enlargement of the spinal cord and the L4, L5 and L6 DRG were dissected and postfixed in 4% PFA for 2 h. Spinal cords were then cryoprotected with 30% sucrose at 41C overnight and then 40 mm thick horizontal sections were cut on a freezing sliding microtome. Free floating spinal cord sections and whole DRG were then stained in 1 Â PBS containing X-gal (5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside) to monitor for b-galactosidase expression. Spinal cord sections were then mounted onto gelatinized slides counterstained with 0.02% neutral red, dehydrated through 70%, 95% and absolute ethanol, cleared with Histocleart and coverslipped with DpX.
